Confronti finanziari Novo Nordisk A/S

Azioni

Mercato chiuso - Nasdaq Copenhagen Altri mercati azionari 17:20:00 12/06/2025			Variaz. 5gg	Var. 1 gen.
519,20 ^DKK	+0,48%		+8,92%	-16,82%

05:10	Novo Nordisk avvia lo sviluppo avanzato del trattamento per la gestione del peso corporeo Amycretin	MT
12/06	Novo Nordisk si prepara a lanciare studi clinici avanzati per il farmaco sperimentale contro l'obesità amycretin	RE

Aggiungi a un elenco 0 selezionato Solo clienti o iscritti possono usare questa funzione Accedi Registrati	Fatturato (N-1)	Margine netto (N-1)	Margine EBIT (N-1)	ROE (N-1)	ROA (N-1)	Leverage (N-1)
NOVO NORDISK A/S	40,31 Mrd	34,78%	44,19%	80,78%	25,88%	0.52x
ELI LILLY AND COMPANY	45,04 Mrd	23,51%	31,78%	84,84%	14,84%	1.88x
JOHNSON & JOHNSON	88,82 Mrd	15,84%	29,8%	34,23%	13,95%	0.36x
ABBVIE INC.	56,33 Mrd	7,59%	41,43%	263,08%	13,34%	2.56x
ROCHE HOLDING AG	66,76 Mrd	13,68%	34,42%	43,45%	15,69%	0.74x
NOVARTIS AG	50,32 Mrd	23,73%	38,74%	34,74%	15,58%	0.85x
ASTRAZENECA PLC	54,07 Mrd	13,01%	31,31%	32,11%	12,51%	1.47x
MERCK & CO., INC.	64,17 Mrd	26,68%	36,46%	46,35%	17,38%	0.86x
AMGEN INC.	33,42 Mrd	12,24%	44,96%	177,29%	11,36%	2.33x
PFIZER, INC.	63,63 Mrd	12,62%	34,24%	19,99%	8,05%	1.52x
GILEAD SCIENCES, INC.	28,75 Mrd	1,67%	29,63%	27,6%	9,57%	1.48x
SANOFI	42,53 Mrd	13,98%	27,61%	11,75%	4,43%	0.68x
VERTEX PHARMACEUTICALS INCORPORATED	11,02 Mrd	-4,86%	6,31%	0,65%	0,49%	-6.77x
BRISTOL-MYERS SQUIBB COMPANY	48,3 Mrd	-18,53%	10,77%	10,23%	-9,53%	6.49x
CHUGAI PHARMACEUTICAL CO., LTD.	7,45 Mrd	33,09%	46,3%	22%	18,71%	-1.74x
GSK PLC	39,28 Mrd	8,21%	29,16%	48,09%	10,97%	1.22x
JIANGSU HENGRUI MEDICINE CO., LTD.	3,83 Mrd	22,64%	26,77%	14,73%	13,49%	-2.98x
HALEON PLC	14,06 Mrd	12,84%	22,26%	8,8%	4,22%	2.82x
TAKEDA PHARMACEUTICAL COMPANY LIMITED	28,19 Mrd	3,38%	5,02%	2,1%	0,36%	4.66x
Media	41,38 Mrd	13,48%	30,06%	50,67%	10,59%	1,00x
Media ponderata per Capi.	49,74 Mrd	16,8%	33,26%	71,53%	13,41%	1,14x